Instrument Inactif

Autres langues Tonix Pharmaceuticals Holding Corp Nasdaq

Actions

US8902604094

Produits pharmaceutiques

Autres langues

02/09	Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
18/08	Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer
10/08	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
05/08	Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
03/08	Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US
03/08	Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
27/07	Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
21/07	Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026
15/07	Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease
15/07	Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
13/07	Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage
13/07	Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment
13/07	Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
29/06	Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study
29/06	Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder
29/06	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
11/06	Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
08/06	Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage
08/06	Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA
08/06	Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
28/05	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
28/05	Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting
27/05	Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05	Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody